Literature DB >> 2539271

A new immunoradiometric assay for corticotropin evaluated in normal subjects and patients with Cushing's syndrome.

H Raff1, J W Findling.   

Abstract

We evaluated a new, commercially available two-site immunoradiometric assay (IRMA) for corticotropin (ACTH) in human plasma. The precision and detection limit were an improvement over radioimmunoassay (RIA). Addition of ACTH 1-24 or ACTH 18-39 to plasma containing ACTH 1-39 resulted in a decrease in measured ACTH. Results by both IRMA and RIA are reported and compared for normal subjects, patients with Cushing's disease, and patients with ectopic ACTH. Effects of administering dexamethasone, metyrapone, ACTH 1-24, and corticoliberin were evaluated. The present assay is more sensitive, specific, and reproducible than RIA. The presence of fragments of ACTH or "big" ACTH that are reactive in RIA may lead to artifactually low ACTH concentrations by IRMA. Therefore, RIA may still be necessary for differential diagnosis of ectopic ACTH syndromes. However, the IRMA is an improvement for evaluating pituitary--adrenal function in patients with low concentrations of ACTH in plasma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539271

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  14 in total

1.  Sexually diergic, dose-dependent hypothalamic-pituitary-adrenal axis responses to nicotine in a dynamic in vitro perfusion system.

Authors:  Jessica M McKlveen; Jared M Wilson; Robert T Rubin; Michael E Rhodes
Journal:  J Pharmacol Toxicol Methods       Date:  2010-02-01       Impact factor: 1.950

2.  Neurohormonal and inflammatory hyper-responsiveness to acute mental stress in depression.

Authors:  Ali A Weinstein; Patricia A Deuster; Jennifer L Francis; Robert W Bonsall; Russell P Tracy; Willem J Kop
Journal:  Biol Psychol       Date:  2010-01-29       Impact factor: 3.251

3.  Stimulation of the hypothalamic-pituitary-adrenal axis with the opioid antagonist nalmefene.

Authors:  Eliza B Geer; Rita E Landman; Sharon L Wardlaw; Irene M Conwell; Pamela U Freda
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

4.  A comparison of immunometric and radioimmunoassay measurement of ACTH for the differential diagnosis of Cushing's syndrome.

Authors:  J R Lindsay; V K Shanmugam; E H Oldfield; A T Remaley; L K Nieman
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

5.  Dissociation of ACTH and cortisol in septic and non-septic ICU patients.

Authors:  Hershel Raff; Nebiyu Biru; Neil Reisinger; David J Kramer
Journal:  Endocrine       Date:  2016-07-18       Impact factor: 3.633

Review 6.  POMC: The Physiological Power of Hormone Processing.

Authors:  Erika Harno; Thanuja Gali Ramamoorthy; Anthony P Coll; Anne White
Journal:  Physiol Rev       Date:  2018-10-01       Impact factor: 37.312

7.  Significance of absent prohormone convertase 1/3 in inducing clinically silent corticotroph pituitary adenoma of subtype I--immunohistochemical study.

Authors:  S Ohta; S Nishizawa; Y Oki; T Yokoyama; H Namba
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

8.  In vivo and in vitro effects of glucocorticoids on lymphocyte proliferation in depression.

Authors:  R Rupprecht; N Wodarz; J Kornhuber; K Wild; B Schmitz; H U Braner; O A Müller; P Riederer; H Beckmann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

9.  Characterization of pituitary-adrenocortical activity in the Malayan flying fox (Pteropus vampyrus).

Authors:  DeeAnn M Reeder; Hershel Raff; Thomas H Kunz; Eric P Widmaier
Journal:  J Comp Physiol B       Date:  2006-02-23       Impact factor: 2.200

10.  Adrenocortical responsiveness to infusions of physiological doses of ACTH is not altered in posttraumatic stress disorder.

Authors:  Allen D Radant; Dorcas J Dobie; Elaine R Peskind; M Michele Murburg; Eric C Petrie; Evan D Kanter; Murray A Raskind; Charles W Wilkinson
Journal:  Front Behav Neurosci       Date:  2009-10-30       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.